Filter Results:
(333)
Show Results For
- All HBS Web (333)
- Faculty Publications (142)
Show Results For
- All HBS Web (333)
- Faculty Publications (142)
- January 2008 (Revised January 2008)
- Case
Two Brattle Center: A Mental-Health Clinic in Search of a Viable Operating Model
By: Robert G. Eccles
Two Brattle Center (TBC) is a struggling for-profit private mental health clinic based in Harvard Square. Its founder, Dr. Joan Wheelis, is a nationally recognized practicing psychiatrist who has developed outpatient treatment programs based on Dialectical Behavior... View Details
Keywords: Business Model; For-Profit Firms; Decision Choices and Conditions; Financial Strategy; Health Care and Treatment; Health Disorders; Medical Specialties; Nonprofit Organizations; Emotions; Health Industry; United States
Eccles, Robert G. "Two Brattle Center: A Mental-Health Clinic in Search of a Viable Operating Model." Harvard Business School Case 408-103, January 2008. (Revised January 2008.)
- October 2020 (Revised November 2023)
- Case
COVID-19 Testing at Everlywell
By: Jeffrey J. Bussgang and Olivia Hull
In March 2020, as COVID-19 spreads rapidly across the U.S., Everlywell founder Julia Cheek considers how to respond as a small start-up specializing in at-home lab testing. After making dramatic budget cuts, she decides to pivot the organization to address the... View Details
Keywords: Entrepreneurship; Business Strategy; Venture Capital; Health Care and Treatment; Health Disorders; Leading Change; Technology Adoption; Digital Platforms; Competitive Strategy; Science; Adaptation; Corporate Social Responsibility and Impact; Crisis Management; Social Entrepreneurship; Ethics; Government Legislation; Health; Health Testing and Trials; Health Pandemics; Consumer Products Industry; Health Industry; Technology Industry; Texas; United States
Bussgang, Jeffrey J., and Olivia Hull. "COVID-19 Testing at Everlywell." Harvard Business School Case 821-001, October 2020. (Revised November 2023.)
- Web
Faculty & Research
treating myeloma, but it is far from clinical trials and carries significant uncertainty. The other option is an established company with a promising drug already in Phase II trials, offering the potential for quicker patient impact and a... View Details
- Web
Faculty & Advisors | MBA
way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. TrialSpark is a tech-driven drug development company that can run higher quality clinical... View Details
- Article
Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization
By: Lucy Chen, Richard G. Frank and Haiden A. Huskamp
In late 2020, the Supreme Court began hearing a case challenging the Affordable Care Act (ACA), which led to coverage gains for many low-income, reproductive-age women. To explore potential implications of a full ACA repeal for this population, we examined gains... View Details
Keywords: Medicaid; Women's Health; Health Insurance; Health Care and Treatment; Gender; Insurance; Poverty; Health Industry; United States
Chen, Lucy, Richard G. Frank, and Haiden A. Huskamp. "Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization." Inquiry 57 (2020).
- January 2021
- Case
Value-Based Insurance Design at Onex
By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details
Keywords: Decision Making; Cost vs Benefits; Decision Choices and Conditions; Decisions; Finance; Behavioral Finance; Insurance; Health; Health Care and Treatment; Human Resources; Compensation and Benefits; Markets; Demand and Consumers; Consumer Behavior; Social Psychology; Behavior; Interests; Motivation and Incentives; Perception; Health Industry; Insurance Industry; North America; United States
Schwartzstein, Joshua, Amitabh Chandra, and Amram Migdal. "Value-Based Insurance Design at Onex." Harvard Business School Case 921-023, January 2021.
- 15 Apr 2014
- First Look
First Look: April 15
Purchase this case: http://hbr.org/product/pepsico-profits-and-food-the-belt-tightens/an/314055-PDF-ENG Harvard Business School Case 313-012 Cancer Treatment Centers of America® (A) Cancer Treatment Centers... View Details
Keywords: Sean Silverthorne
- 26 Apr 2023
- Cold Call Podcast
How Martine Rothblatt Started a Company to Save Her Daughter
- 2020
- Working Paper
What Can Economics Say About Alzheimer's Disease?
By: Amitabh Chandra, Courtney Coile and Corina Mommaerts
Alzheimer’s Disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. While there is overlap with the economics of aging, the defining features of the... View Details
Chandra, Amitabh, Courtney Coile, and Corina Mommaerts. "What Can Economics Say About Alzheimer's Disease?" NBER Working Paper Series, No. 27760, August 2020.
- September–October 2020
- Article
The Past, Present, and (Near) Future of Gene Therapy and Gene Editing
By: Julia Pian, Amitabh Chandra and Ariel Dora Stern
Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused... View Details
Keywords: Gene Therapy; Gene Editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change
Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).
- 2024
- Article
Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior
By: Olivia Zhao and Anna D Sinaiko
High out-of-pocket (OOP) prices for prescription drugs create financial difficulties for patients, and cost-related underuse of medications can adversely patient health. Simultaneously, many physicians report a willingness to address affordability concerns with... View Details
Keywords: Price; Health Care and Treatment; Communication Technology; Technology Adoption; Customer Focus and Relationships; Health Industry
Zhao, Olivia, and Anna D Sinaiko. "Effects of a Real-Time Information-Based Intervention on Physician Prescribing Behavior." Academy of Management Best Paper Proceedings 2024, no. 1 (2024).
- 01 Dec 2023
- News
Wide Horizon
There were three critical events that led John Rodakis (MBA 1997) to form the nonprofit N of One in 2014 and ultimately dedicate his life to surfacing breakthrough autism research. The first occurred on Thanksgiving of 2012. He had driven about four hours with his wife... View Details
Keywords: Dan Morrell; Photos by Sarah Wilson
- 02 Mar 2007
- What Do You Think?
What Is the Government’s Role in US Health Care?
Newman), the high cost of new technology, artificial restrictions on the supply of drugs (Sergey Mirkiin) and healthcare providers (David Stahl and Michael Robbins), the size and complexity of the problem itself (James Sullivan),... View Details
- Person Page
Comments on my health
February 22, 2010
The doctors have been pleasantly surprised that I have responded to therapy better than they would have imagined. I have been greatly blessed through the miracle of medical science. I also attribute doing better to the faith and prayers... View Details
- 22 Feb 2024
- News
Combat-Tested Cancer Coaching
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Hi, this is Dan Morrell, host of Skydeck. When Kathy Giusti (MBA 1985) was diagnosed with multiple myeloma in 1996, she was overwhelmed. It was the pre-Internet era, with limited available information, but... View Details
- 25 Jul 2023
- Research & Ideas
Could a Business Model Help Big Pharma Save Lives and Profit?
With Hepatitis C running rampant in Egypt in 2012, Clifford Samuel, then of California-based Gilead Sciences, convened a series of urgent meetings with Egyptian government officials, doctors, and patients. His goal? To make Gilead’s lifesaving Hepatitis C View Details
- 05 Dec 2017
- First Look
First Look at New Research and Ideas, December 5, 2017
scientific collaborators. We generated exogenous variation in search costs for pairs of potential collaborators by randomly assigning individuals to 90-minute structured information-sharing sessions as part of a grant funding opportunity. We estimate that the View Details
Keywords: Sean Silverthorne
- 21 Apr 2009
- First Look
First Look: April 21, 2009
Industry Location Author:Arthur A. Daemmrich Abstract A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a... View Details
Keywords: Martha Lagace
- 15 Jul 2013
- Research & Ideas
Five Imperatives for Improving Health Care
Innovation in health care treatment seems to far outpace innovation in health care business management. Just ask President Obama—two weeks ago he delayed enactment of a key provision of the new health care law for fear its requirements... View Details
- 2024
- Article
Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway
By: Mateo Aboy, Cristina Crespo and Ariel Stern
Moderate-risk medical devices constitute 99% of those that have been regulated by the U.S. Food and Drug Administration (FDA) since it gained authority to regulate medical technology nearly five decades ago. This article presents an analysis of the interaction between... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Technology Adoption; Technological Innovation; Safety; Medical Devices and Supplies Industry; United States
Aboy, Mateo, Cristina Crespo, and Ariel Stern. "Beyond the 510(k): The Regulation of Novel Moderate-Risk Medical Devices, Intellectual Property Considerations, and Innovation Incentives in the FDA’s De Novo Pathway." Art. 29. npj Digital Medicine 7 (2024).